Pure Global
NCT00317681

Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)

The Efficacy of Topical Tacrolimus in the Treatment of Cutaneous Lupus Erythematosus - a Multi-Center-Trial
Heinrich-Heine University, Duesseldorf·Phase 2·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cutaneous Lupus Erythematosus
Drug/Device/Intervention
Tacrolimus ointment
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Heinrich-Heine University, Duesseldorf
Location
Duesseldorf, Germany
Timeline & enrollment
Phase
Phase 2
Start date
Aug 01, 2005
End date
Feb 01, 2007
Enrollment
30 participants
Primary outcome

Difference in skin lesions of patients with CLE before (begin of study) and after treatment (end of study) evaluated by a clinical score

Summary

The purpose of this study is to evaluate the efficacy of topical tacrolimus in different
 subtypes of cutaneous lupus erythematosus. As shown by several groups activated memory T
 lymphocytes play a key role in the pathogenesis of lupus erythematosus. Tacrolimus targets T
 lymphocytes and suppresses their activation by inhibiting the expression of cytokine genes,
 such as IL-2. Therefore, treatment of cutaneous lupus erythematosus with topical tacrolimus
 might result in an improvement of skin lesions in such patients.

ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00317681
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00317681 through Pure Global AI's free database. This Phase 2 trial is sponsored by Heinrich-Heine University, Duesseldorf and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.